Stock Report: BioTime Inc. (BTX) Report Updated: May 13, 2013 | Print This Page

BioTime, Inc., a biotechnology company, focuses on regenerative medicine and blood plasma volume expanders. It primarily focuses on regenerative medicine, which refers to therapies based on human embryonic stem (hES) cell and induced pluripotent stem (iPS) cell technology designed to rebuild cell and tissue function lost due to degenerative disease or injury. The company develops and markets research products in the field of stem cells and regenerative medicine. It develops therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases; cardiovascular and blood diseases; therapeutic applications of stem cells to treat orthopedic diseases, injuries, and cancer; and retinal cell product for use in the treatment of age-related macular degeneration. The company also markets approximately 140 human embryonic progenitor cell types made using the ACTCellerate technology; an array of hES cell lines carrying inherited genetic diseases, such as cystic fibrosis and muscular dystrophy; ESpan cell growth media designed for the growth of human embryonic progenitor cell types; and ESpy cell lines, the derivatives of hES cells would emit beacons of light. In addition, it develops blood plasma volume expanders, blood replacement solutions for hypothermic surgery, organ preservation solutions, and technology for use in surgery, emergency trauma treatment, and other applications. Its lead blood plasma expander product, Hextend, is a physiologically balanced intravenous solution that maintains circulatory system fluid volume and blood pressure and helps sustain vital organs during surgery. Further, the company involves in developing another blood volume replacement product, PentaLyte, formulated to maintain the patient’s tissue and organ function by sustaining the patient’s fluid volume and physiological balance. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California.